VASCULITIS SYNDROMES: Edited by Hasan Yazici and Yusuf YaziciTakayasu arteritis: an updateSeyahi, Emire Author Information Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey Correspondence to Dr Emire Seyahi, MD, Professor of Medicine, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul 81310, Turkey. Tel: +90 0212 414 30 00; fax: +90 0212 589 08 08; e-mail: [email protected] Current Opinion in Rheumatology 29(1):p 51-56, January 2017. | DOI: 10.1097/BOR.0000000000000343 Buy Metrics Abstract Purpose of review Takayasu arteritis has long been considered as an uncommon disease, rather specific to the Far-East; however recent surveys show that the disease can be seen in all ethnicities around the world with increasing prevalence rates. Nowadays, it would not be fair to consider Takayasu arteritis as a rare disease. Recent findings Although involvement of the thoracic aorta and its branches was more common among females, males had a tendency toward limited involvement of the abdominal aorta and its branches. Pregnancy seems to cause serious risks for both maternal and fetal health. Takayasu arteritis frequently coexist with inflammatory bowel diseases and the two diseases may have common genetic background and molecular pathways. New imaging tools such as computerized tomography or magnetic resonance angiography, fludeoxyglucose positron emission tomography-computerized tomography and recently contrast-enhanced ultrasonography are frequently used in the diagnosis and to assess vascular inflammation. Accumulating evidence shows that biological agents such as anti-tumor necrosis factor agents, tocilizumab and rituximab could be used effectively in refractory cases. The restenosis or occlusion risks are still high with vascular interventions. The mortality seems to be decreasing in recent years. Summary The ethiopathogenesis of the disease should be clarified. Our feature goals should be to discriminate better active inflammation from quiescent disease enabling more effective treatment. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.